Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

• Revenue in CAD (TTM)19.38m
• Net income in CAD-53.33m
• Incorporated2014
• Employees131.00

• Location
  Profound Medical Corp2400 Skymark Ave Unit 6MISSISSAUGA L4W 5K5CanadaCAN
• Phone+1 (647) 476-1350
• Fax+1 (647) 476-1350
• Websitehttps://profoundmedical.com/